WebApr 11, 2024 · CENTRAL TRUST Co trimmed its position in Bio-Rad Laboratories, Inc. (NYSE:BIO – Get Rating) by 74.5% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 135 shares of the medical research company’s stock after … WebJul 27, 2024 · 10x's Tuesday SEC filing related to the global settlement says the company also agreed to pay Bio-Rad over $29 million in royalties and interest related to sales of GEM products from the date of ...
Bio-Rad Laboratories, Inc. - Financials - SEC Filings
WebInvestor Relations Financial Reports & SEC Filings Financial Reports. QIAGEN N.V.reports its annual results under U.S. GAAP (SEC filing) due to the listing of our stock at the New York Stock Exchange. As a company established under the laws of The Netherlands we are required by law to also report under IFRS accounting standards. WebFeb 17, 2024 · HERCULES, Calif.—February 16, 2024 -- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, … imbalanced nutrition rationale
Qiagen N.V. - Investor Relations - Financial Reports & SEC Filings ...
WebApr 10, 2024 · Sumitomo Mitsui DS Asset Management Company Ltd raised its position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO – Get Rating) by 1.7% in the fourth quarter, according to its most recent ... WebApr 10, 2024 · The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 27.40% of the stock is owned by company insiders. Bio-Rad Laboratories Price Performance WebJan 9, 2024 · All companies, foreign and domestic, are required to file registration statements, periodic reports, and other forms electronically through EDGAR. list of ingredients in herbs de provence